12:00 AM
Jul 13, 2009
 |  BC Week In Review  |  Company News  |  Deals

Elan, PharmatrophiX deal

PharmatrophiX granted Elan an exclusive, worldwide license to develop and commercialize its two preclinical compounds targeting p75...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >